Developer docs
API playgroundTry for free, no card

Search company profiles

Double Blind Bio

Full company profile

uuid00eteeq

Namestring
Double Blind Bio
Legal namestring
Double Blind Bio, Inc.
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Double Blind Bio (legal entity Double Blind Bio, Inc., Delaware corporation) builds agentic AI infrastructure for clinical trial workflows, serving both trial sponsors (biotech and pharma companies, plus Contract Research Organizations) and clinical research sites. The platform deploys AI agents that automate work across the trial lifecycle — site identification, feasibility processing, study startup, ongoing trial engagement, and post-award monitoring — functioning inside existing sponsor and site systems rather than as standalone tools. The product is modular: sponsors use Site Selection + Feasibility, Study Startup, and Site Engagement modules, while sites use a Growth Module (trial discovery), Form Automation (AI pre-fill of feasibility responses), Mission Control (overnight monitoring of SUSARs, amendments, visit windows, and expiring approvals), and an AI-Powered Intelligent Assistant for BD outreach. All modules are anchored on a curated, dynamically updated database of clinical trial sites with advanced filtering on therapeutic area, experience, geographic reach, patient population, and historical performance.

The company operates a B2B SaaS model with annual subscription pricing (not publicly disclosed), accessed through a demo-based enterprise sales motion targeting both sponsor-side biotech/pharma teams and site-side clinical research organizations. Distribution is direct enterprise sales combined with inside sales for mid-market accounts, supported by content marketing via a company blog and product pages. The company sells to two primary buyer personas — life sciences companies (biotech/pharma) seeking faster site selection and activation without headcount additions, and clinical research sites seeking faster trial discovery and lower administrative burden on BD and feasibility teams. CROs are identified as a secondary segment.

Founded in 2025 and headquartered in San Francisco, Double Blind Bio is led by CEO and co-founder Shruti Tibrewala (previously at Flatiron Health and Novartis; Stanford B.S., Berkeley MBA/MPH) and CTO and co-founder Dave Hughes. The team draws from Google, Verily, Flatiron Health, and Stanford. The company is venture-backed by Define Ventures, SignalFire, and Peterson Ventures, having raised approximately $5.6 million as of December 2025, and was named one of 10 AI-based pharmaceutical startups to watch in 2026 by StartUs Insights. The operating footprint extends to U.S. and international customers per the company's terms of service.

Short descriptiontext

Double Blind Bio builds agentic AI infrastructure that automates site identification, feasibility, study startup, and trial execution workflows for biotech and pharma sponsors and clinical research sites. Founded 2025, headquartered in San Francisco, backed by Define Ventures, SignalFire, and Peterson Ventures.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial automation, agentic AI infrastructure, clinical site selection, feasibility automation software, trial startup platform
Industry3 codes
PRIMARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Software
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Subscription
TypeSubscription Recurring
Description

Software-as-a-service platform with subscription-based access to AI agents for clinical trial site selection, feasibility automation, and business development. Organizations pay recurring fees for access to the platform, database, and AI-powered tools. Subscription automatically renews at end of each billing period unless cancelled.

doubleblindbio.co
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Subscription-based SaaS with organization-level access
ModelSubscriptionBilling cadenceAnnual
Notes

Terms specified in user account. Automatic renewal at billing period end unless cancelled. 48 hours notice required to avoid next billing cycle charge. No pro-rated refund upon cancellation.

doubleblindbio.co
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Double Blind Bio provides an AI-powered agentic infrastructure platform that automates clinical trial workflows for both sponsors and sites. The platform deploys AI agents that handle site selection, feasibility response generation, study startup, document routing, and ongoing trial execution. Sponsors use modules including Site Selection + Feasibility, Study Startup, and Site Engagement; sites use the Growth Module, Form Automation, and Mission Control, all backed by a curated, dynamically updated clinical research site database.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Sites save 5+ hours every week by reducing manual sponsor outreach, feasibility, and startup admin
+4 more records
Product overview1 text field

Double Blind Bio offers a unified agentic infrastructure platform for clinical trials, combining AI agents that automate workflows across the trial lifecycle. The platform serves both sponsors (biotech, pharma, CROs) and clinical research sites through interconnected modules. For sponsors: Site Selection + Feasibility, Study Startup, and Site Engagement modules. For sites: Growth Module, Form Automation, and Mission Control. The AI-Powered Intelligent Assistant connects both audiences. All modules share a curated site database and compound intelligence across trials.

Product and service1 record
1Agentic Infrastructure Platform
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Deep 6 AI
TypeDirect peer
Description

AI-powered clinical trial patient and site matching platform that mines EHR data to accelerate trial recruitment and feasibility. Targets the same sponsor and site workflows as Double Blind Bio.

TypeDirect peer
Description

Site identification and feasibility platform helping sponsors find the right investigative sites. Closely overlaps with Double Blind Bio's Site Selection + Feasibility module.

TypeDirect peer
Description

Decentralized clinical trial technology platform serving sponsors and sites with digital trial infrastructure. Adjacent overlap with DBB on trial startup automation and site workflow tools.

TypeBroad incumbent
Description

Public, large-scale provider of cloud software for life sciences including Veeva Vault CTMS for clinical trial management. Represents the incumbent platform that DBB must displace or integrate with.

TypeBroad incumbent
Description

Largest global CRO with extensive clinical trial technology, including AI-driven site identification and feasibility tools. The dominant incumbent that DBB competes against for sponsor mindshare.

TypeEmerging player
Description

Clinical trial matching and recruitment platform using structured data to connect patients and sites with relevant trials. Overlaps with DBB's Growth Module and site-discovery capabilities.

7Mendel
TypeDirect peer
Description

AI platform purpose-built for clinical trial operations, including site feasibility, study design, and patient cohort identification. Directly comparable to Double Blind Bio in applying AI agents to clinical trial workflows.

TypeEmerging player
Description

Tech-enabled clinical trial site network focused on bringing modern infrastructure to under-served patient populations. Potential partner/competitor at the site-network layer where DBB also operates.

TypeBroad incumbent
Description

Major clinical trial technology platform (Rave EDC, eCOA, RTSM) serving pharma sponsors and CROs. Broad incumbent with overlapping capabilities in clinical trial operations and site workflows.

10TrialSpark (now Tempus Clinical)
TypeEmerging player
Description

Tech-forward clinical trial operations platform (acquired by Tempus) that modernizes trial execution including site activation and study startup. Directly comparable in automating startup workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Double Blind Bio

Clinical Trial Softwaredoubleblindbio.co

Double Blind Bio builds agentic AI infrastructure that automates site identification, feasibility, study startup, and trial execution workflows for biotech and pharma sponsors and clinical research sites. Founded 2025, headquartered in San Francisco, backed by Define Ventures, SignalFire, and Peterson Ventures.

What Double Blind Bio does

Double Blind Bio (legal entity Double Blind Bio, Inc., Delaware corporation) builds agentic AI infrastructure for clinical trial workflows, serving both trial sponsors (biotech and pharma companies, plus Contract Research Organizations) and clinical research sites. The platform deploys AI agents that automate work across the trial lifecycle — site identification, feasibility processing, study startup, ongoing trial engagement, and post-award monitoring — functioning inside existing sponsor and site systems rather than as standalone tools. The product is modular: sponsors use Site Selection + Feasibility, Study Startup, and Site Engagement modules, while sites use a Growth Module (trial discovery), Form Automation (AI pre-fill of feasibility responses), Mission Control (overnight monitoring of SUSARs, amendments, visit windows, and expiring approvals), and an AI-Powered Intelligent Assistant for BD outreach. All modules are anchored on a curated, dynamically updated database of clinical trial sites with advanced filtering on therapeutic area, experience, geographic reach, patient population, and historical performance.

The company operates a B2B SaaS model with annual subscription pricing (not publicly disclosed), accessed through a demo-based enterprise sales motion targeting both sponsor-side biotech/pharma teams and site-side clinical research organizations. Distribution is direct enterprise sales combined with inside sales for mid-market accounts, supported by content marketing via a company blog and product pages. The company sells to two primary buyer personas — life sciences companies (biotech/pharma) seeking faster site selection and activation without headcount additions, and clinical research sites seeking faster trial discovery and lower administrative burden on BD and feasibility teams. CROs are identified as a secondary segment.

Founded in 2025 and headquartered in San Francisco, Double Blind Bio is led by CEO and co-founder Shruti Tibrewala (previously at Flatiron Health and Novartis; Stanford B.S., Berkeley MBA/MPH) and CTO and co-founder Dave Hughes. The team draws from Google, Verily, Flatiron Health, and Stanford. The company is venture-backed by Define Ventures, SignalFire, and Peterson Ventures, having raised approximately $5.6 million as of December 2025, and was named one of 10 AI-based pharmaceutical startups to watch in 2026 by StartUs Insights. The operating footprint extends to U.S. and international customers per the company's terms of service.

Double Blind Bio firmographics

Firmographics
Name
Double Blind Bio
Legal name
Double Blind Bio, Inc.
Website
https://doubleblindbio.co
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Double Blind Bio builds agentic AI infrastructure that automates site identification, feasibility, study startup, and trial execution workflows for biotech and pharma sponsors and clinical research sites. Founded 2025, headquartered in San Francisco, backed by Define Ventures, SignalFire, and Peterson Ventures.
Ownership category
akta.pro rank

Double Blind Bio industry classification

Industry
Product category
Clinical Trial Software
NAICS
Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGACAC
Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts)
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial automation
  • Agentic AI infrastructure
  • Clinical site selection
  • Feasibility automation software
  • Trial startup platform

Where Double Blind Bio is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Double Blind Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. SaaS Subscription: Software-as-a-service platform with subscription-based access to AI agents for clinical trial site selection, feasibility automation, and business development. Organizations pay recurring fees for access to the platform, database, and AI-powered tools. Subscription automatically renews at end of each billing period unless cancelled.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based SaaS with organization-level access

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Double Blind Bio product offering

Product offering

Core offering

Double Blind Bio provides an AI-powered agentic infrastructure platform that automates clinical trial workflows for both sponsors and sites. The platform deploys AI agents that handle site selection, feasibility response generation, study startup, document routing, and ongoing trial execution. Sponsors use modules including Site Selection + Feasibility, Study Startup, and Site Engagement; sites use the Growth Module, Form Automation, and Mission Control, all backed by a curated, dynamically updated clinical research site database.

Product overview

Double Blind Bio offers a unified agentic infrastructure platform for clinical trials, combining AI agents that automate workflows across the trial lifecycle. The platform serves both sponsors (biotech, pharma, CROs) and clinical research sites through interconnected modules. For sponsors: Site Selection + Feasibility, Study Startup, and Site Engagement modules. For sites: Growth Module, Form Automation, and Mission Control. The AI-Powered Intelligent Assistant connects both audiences. All modules share a curated site database and compound intelligence across trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • Agentic Infrastructure Platform

Quantifiable outcome

  • Sites save 5+ hours every week by reducing manual sponsor outreach, feasibility, and startup admin
  • +4 more outcomes

Companies that use Double Blind Bio

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Double Blind Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature10 records

Double Blind Bio partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Double Blind Bio competitors and assessment

Company assessment

Direct peers

  • Deep 6 AI: AI-powered clinical trial patient and site matching platform that mines EHR data to accelerate trial recruitment and feasibility. Targets the same sponsor and site workflows as Double Blind Bio.
  • Trial Library: Site identification and feasibility platform helping sponsors find the right investigative sites. Closely overlaps with Double Blind Bio's Site Selection + Feasibility module.
  • Medable: Decentralized clinical trial technology platform serving sponsors and sites with digital trial infrastructure. Adjacent overlap with DBB on trial startup automation and site workflow tools.
  • Mendel: AI platform purpose-built for clinical trial operations, including site feasibility, study design, and patient cohort identification. Directly comparable to Double Blind Bio in applying AI agents to clinical trial workflows.

Broad incumbents

  • Veeva Systems: Public, large-scale provider of cloud software for life sciences including Veeva Vault CTMS for clinical trial management. Represents the incumbent platform that DBB must displace or integrate with.
  • IQVIA: Largest global CRO with extensive clinical trial technology, including AI-driven site identification and feasibility tools. The dominant incumbent that DBB competes against for sponsor mindshare.
  • Medidata (Dassault Systèmes): Major clinical trial technology platform (Rave EDC, eCOA, RTSM) serving pharma sponsors and CROs. Broad incumbent with overlapping capabilities in clinical trial operations and site workflows.

Emerging players

  • Antidote: Clinical trial matching and recruitment platform using structured data to connect patients and sites with relevant trials. Overlaps with DBB's Growth Module and site-discovery capabilities.
  • Paradigm Health: Tech-enabled clinical trial site network focused on bringing modern infrastructure to under-served patient populations. Potential partner/competitor at the site-network layer where DBB also operates.
  • TrialSpark (now Tempus Clinical): Tech-forward clinical trial operations platform (acquired by Tempus) that modernizes trial execution including site activation and study startup. Directly comparable in automating startup workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Double Blind Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Double Blind Bio leadership team

Management profile

Number of profiles

Profiles10 records

Double Blind Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Double Blind Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Double Blind Bio

What does Double Blind Bio do?

Double Blind Bio provides an AI-powered agentic infrastructure platform that automates clinical trial workflows for both sponsors and sites. The platform deploys AI agents that handle site selection, feasibility response generation, study startup, document routing, and ongoing trial execution. Sponsors use modules including Site Selection + Feasibility, Study Startup, and Site Engagement; sites use the Growth Module, Form Automation, and Mission Control, all backed by a curated, dynamically updated clinical research site database.

Is Double Blind Bio a public or private company?

Double Blind Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Double Blind Bio founded?

Double Blind Bio was founded in 2025. It employs 1 to 10 people.

Where is Double Blind Bio based?

Double Blind Bio is headquartered in San Francisco, United States, in the North America region.

How does Double Blind Bio make money?

One revenue line is on record: saaS Subscription.

Who are Double Blind Bio's main competitors?

Direct peers on record are Deep 6 AI, Trial Library, Medable and Mendel. Broad incumbents are Veeva Systems, IQVIA and Medidata (Dassault Systèmes). Emerging players are Antidote, Paradigm Health and TrialSpark (now Tempus Clinical).

Does Double Blind Bio have an API?

No public API is recorded for Double Blind Bio.

What industry is Double Blind Bio in?

Double Blind Bio's product category is Clinical Trial Software. Its primary akta.pro industry code is HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation), with a secondary code of HLAGACAC, Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts). Its NAICS code is 5132 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales